Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2003-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/j.1538-7836.2003.00383.xPMID 12941043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)

  2002cited by this paper
• Localization and Identification of Thrombin and Plasminogen Activator Activities in Model Human Thrombi by in situ Zymography

  2002cited by this paper
• Enhancement of Endogenous Plasminogen Activator-induced Thrombolysis by Argatroban and APC and Its Control by TAFI, Measured in An Arterial Thrombolysis Model In Vivo Using Rat Mesenteric Arterioles

  2002cited by this paper
• Human Thrombi Contain an Abundance of Active Thrombin

  2001cited by this paper
• Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin

  2001cited by this paper
• Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u‐PA‐dependent mechanism

  2001cited by this paper
• Basic principles in thrombolysis: regulatory role of plasminogen.

  2001cited by this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Does not Inhibit In Vitro Thrombolysis by Pharmacological Concentrations of t-PA

  2001cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000cited by this paper
• Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage*

  2000cited by this paper
• An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.

  2000cited by this paper
• Proteolytic activation of purified human procarboxypeptidase U.

  2000cited by this paper
• Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism

  1999cited by this paper
• A Novel Approach to Arterial Thrombolysis

  1999cited by this paper
• Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B

  1999cited by this paper
• A novel approach to arterial thrombolysis.

  1999cited by this paper
• Thrombomodulin in Human Plasma Contributes to Inhibit Fibrinolysis through Acceleration of Thrombin-dependent Activation of Plasma Procarboxypeptidase B

  1998cited by this paper
• Human Procarboxypeptidase U, or Thrombin-activable Fibrinolysis Inhibitor, Is a Substrate for Transglutaminases

  1998cited by this paper
• Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.

  1998cited by this paper
• The inactivation of single‐chain urokinase‐type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin

  1998cited by this paper
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C*

  1998cited by this paper
• Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin(desF1)

  1997cited by this paper
• The Polymerization Pocket “a” within the Carboxyl-terminal Region of the γ Chain of Human Fibrinogen Is Adjacent to but Independent from the Calcium-binding Site*

  1997cited by this paper
• On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B*

  1997cited by this paper
• Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis

  1997cited by this paper
• Thrombi Formed in a Chandler Loop Mimic Human Arterial Thrombi in Structure and PAI-1 Content and Distribution

  1997cited by this paper
• Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis

  1997cited by this paper
• The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

  1996cited by this paper
• Proteins of the Fibrinolytic System in Human Thrombi

  1996cited by this paper
• Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.

  1996cited by this paper
• Inducible carboxypeptidase activity. A role in clot lysis in vivo.

  1996cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• Evidence for an active fibrinolytic system in normal human bone marrow

  1996cited by this paper
• Plasma carboxypeptidases as regulators of the plasminogen system.

  1995cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy

  1995cited by this paper
• The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.

  1995cited by this paper
• Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

  1994cited by this paper
• Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis

  1994cited by this paper
• The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.

  1993cited by this paper
• Factors Contributing to Increased Vascular Fibrinolytic Activity in Mongrel Dogs

  1993cited by this paper
• Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.

  1993cited by this paper
• Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.

  1993cited by this paper
• The Roles of α2-Antiplasmin and Plasminogen Activator Inhibitor 1 (PAI-1) in the Inhibition of Clot Lysis

  1993cited by this paper
• Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK.

  1992cited by this paper
• Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines.

  1991cited by this paper
• Role of α2-Antiplasmin in Fibrin-Specific Clot Lysis with Single-Chain Urokinase-Type Plasminogen Activator in Human Plasma

  1991cited by this paper
• Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma.

  1991cited by this paper
• Initiation of the Protein C Pathway

  1991cited by this paper
• A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

  1991cited by this paper
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

  1990cited by this paper
• Purification and characterization of a new arginine carboxypeptidase in human serum.

  1990cited by this paper
• An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits.

  1989cited by this paper
• Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.

  1988cited by this paper
• Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).

  1988cited by this paper
• The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.

  1986cited by this paper
• Thrombin activity of fibrin thrombi and soluble plasmic derivatives.

  1983cited by this paper
• On the Regulation and Control of Fibrinolysis

  1980cited by this paper

• Endothelial cell source dictates the expression and release of fibrinolytic markers in a proinflammatory environment

  2025influential citation
• Atorvastatin-mediated inhibition of prenylation of Rab27b and Rap1a in platelets attenuates their prothrombotic capacity and modulates clot structure

  2023cites this paper
• Fibrinolysis: an illustrated review

  2023cites this paper
• The suboptimal fibrinolytic response in COVID‐19 is dictated by high PAI‐1

  2022cites this paper
• The Efficacy of Fibrinogen Concentrates in Relation to Cryoprecipitate in Restoring Clot Integrity and Stability against Lysis

  2022cites this paper
• “Going with the flow” in modeling fibrinolysis

  2022cites this paper
• Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

  2021cites this paper
• The Utility and Potential of Mathematical Models in Predicting Fibrinolytic Outcomes.

  2021cites this paper
• Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi

  2021cites this paper
• LRP-1 Mediated Endocytosis of EFE Across the Blood–Brain Barrier; Protein–Protein Interaction and Molecular Dynamics Analysis

  2020cites this paper
• Fibrin in Nerve Tissue Engineering

  2020cites this paper
• Physiology of Haemostasis: Plasmin-Antiplasmin System

  2020cites this paper
• A new pedigree with thrombomodulin‐associated coagulopathy in which delayed fibrinolysis is partially attenuated by co‐inherited TAFI deficiency

  2020cites this paper
• LRP-1 Mediated Endocytosis of EFE Across the Blood–Brain Barrier; Protein–Protein Interaction and Molecular Dynamics Analysis

  2020cites this paper
• Category : Thrombosis and Hemostasis Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Running title : Defective TAFI activation in hemophilia A

  2018cites this paper
• Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.

  2018cites this paper
• The role of barrels 1 and 2 in the enzymatic activity of factor XIII‐A

  2018cites this paper
• The role of β‐barrels 1 and 2 in the enzymatic activity of factor XIII A‐subunit

  2018cites this paper
• An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH

  2018cites this paper
• Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen γ' as thrombomobulin II.

  2017cites this paper
• Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target

  2017cites this paper
• Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus

  2017cites this paper
• Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus

  2017cites this paper
• Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.

  2016cites this paper
• Plasmin-Antiplasmin System

  2016cites this paper
• Impact of Thrombomodulin and Thrombin-Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban

  2016cites this paper
• THROMBOSIS AND HEMOSTASIS Altered fi brinolysis in autosomal dominant thrombomodulin-associated coagulopathy

  2016cites this paper
• Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.

  2015cites this paper
• Basic mechanisms and regulation of fibrinolysis

  2015cites this paper
• Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin

  2014cites this paper
• Regulation of expression of CPB2, the gene encoding human thrombin activatable fibrinolysis inhibitor (TAFI): the role for post-transcriptional regulation

  2014cites this paper
• Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm

  2014cites this paper
• Characterisation, development and application of a clinical model of thrombosis and fibrinolysis

  2014cites this paper
• Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

  2013cites this paper
• Substrates of Factor XIII-A: roles in thrombosis and wound healing.

  2013cites this paper
• Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

  2013cites this paper
• Regulation of fibrinolysis by C‐terminal lysines operates through plasminogen and plasmin but not tissue‐type plasminogen activator

  2012cites this paper
• Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

  2011cites this paper
• Regulation of the Gene Encoding Thrombin-Activable Fibrinolysis Inhibitor in Non-Hepatic Cells

  2011cites this paper
• Secretion and antifibrinolytic function of thrombin‐activatable fibrinolysis inhibitor from human platelets

  2010cites this paper
• Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis

  2010cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• The Role of Thrombin-Activatable Fibrinolysis Inhibitor in the Pathophysiology of Hemostasis

  2010cites this paper
• Ensembles of uncertain mathematical models can identify network response to therapeutic interventions.

  2010cites this paper
• Activation of single‐chain urokinase‐type plasminogen activator by platelet‐associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets

  2010cites this paper
• Effect of the small molecule plasminogen activator inhibitor‐1 (PAI‐1) inhibitor, PAI‐749, in clinical models of fibrinolysis

  2010cites this paper
• Computational Modeling And Simulation Of Thrombus Formation

  2009influential citation
• Secretion and Antifibrinolytic Function of TAFI from Human Platelets

  2009cites this paper
• Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency

  2008cites this paper
• The use of the Chandler loop to examine the interaction potential of NXY‐059 on the thrombolytic properties of rtPA on human thrombi in vitro

  2008influential citation
• Metallocarboxypeptidases: emerging drug targets in biomedicine.

  2007cites this paper
• Aging of Acute Deep Vein Thrombosis Measured by Radiolabeled 99mTc-rt-PA

  2007cites this paper
• Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma

  2007cites this paper
• Das TAFI-System

  2007cites this paper
• Factores de la coagulación y de la fibrinolisis relacionados con la cardiopatía isquémica precoz.

  2007cites this paper
• TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots

  2007cites this paper
• Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit.

  2006cites this paper
• Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.

  2006cites this paper
• Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models

  2006cites this paper
• Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

  2005cites this paper
• Production of Recombinant Human Microplasminogen and Pilot Study in Inducing Posterior Vitreous Detachment

  2005cites this paper
• A Carboxypeptidase Inhibitor from the Tick Rhipicephalus bursa

  2005cites this paper
• Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

  2005cites this paper
• TAFI: regulating the cross talk between coagulation and fibrinolysis TAFI: Regulierung der Wechselwirkung zwischen Gerinnung und Fibrinolyse

  2005cites this paper
• Structural and functional studies on proteinaceous metallocarboxypeptidase inhibitors

  2005cites this paper
• Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin*

  2004cites this paper
• Role of Kinetic Intermediates in the Folding of Leech Carboxypeptidase Inhibitor*

  2004cites this paper
• Plasma Thrombin-Activatable Fibrinolytic Inhibitor ( TAFI ) among Healthy Subjects and Patients with Vascular Diseases : A Validation Study

  2004cites this paper
• TAFI: a promising drug target?

  2004cites this paper
• Plasma Thrombin-Activatable Fibrinolytic Inhibitor (TAFI) among Healthy Subjects and Patients with Vascular Diseases: A Validation Study

  2003cites this paper
• Regulation of Fibrinolysis by Thrombin Activatable Fibrinolysis Inhibitor, an Unstable Carboxypeptidase B That Unites the Pathways of Coagulation and Fibrinolysis

  2001cites this paper